AstraZeneca wins Losec ruling
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ASTRAZENECA yesterday won an early skirmish in defence of its pounds 3bn ulcer drug Losec. An appeal court in Germany upheld a ruling that will block two German companies, Ratiopharm and Merckle, from selling cheap generic copies of Losec for the time being. "We think this strengthens our position," said AstraZeneca spokesman Staffan Ternby.
Losec is the world's top-selling drug with $4.8bn sales last year. As one of the first countries where patents expire, Germany is a key test ground. Losec sales in Germany last year were $185m, 4 per cent of the total.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments